18F-FES PET/CT in Imaging Patients With Desmoid Tumors



Status:Active, not recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:April 2015
End Date:December 2018

Use our guide to learn which trials are right for you!

Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors

This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron
emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors.
18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off
radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may
show where tumor cells with estrogen receptors can be found in the body.

PRIMARY OBJECTIVES:

I. Establish the avidity of desmoid tumors on 18F-FES PET/CT imaging. II. Correlate 18F-FES
PET avidity with degree of estrogen receptor (ER) expression by immunohistochemistry (IHC).

OUTLINE:

Patients undergo 18F-FES PET/CT imaging over 30 minutes.

After completion of study, patients are followed up for 30 days.

Inclusion Criteria:

- Patients with biopsy-proven extra-abdominal desmoid tumors

- Not currently on estrogen medication for birth control, menopause, or other reason

- No anti-estrogen therapy for desmoid tumor within the past 6 months

- Both sporadic desmoid tumors and those associated with familial adenomatous polyposis
(FAP) syndromes will be included

Exclusion Criteria:

- Pregnancy or nursing patients

- Patients who do not wish to participate
We found this trial at
1
site
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Katherine Hartley
Phone: 615-343-7185
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials